🧬
Healthcare & Biotech Myopic Strategy & Over-Diversification 2006 - 2025

23andMe:为什么消费级基因检测的开创者,会把公司带到破产这一步?

检测是一次性消费,而它把希望寄托在回报周期以十年计的新药研发上

23andMe:巅峰期消费级基因检测的开创者,累计检测用户超过千万,上市后估值一度达数十亿美元;终局是核心检测业务增长见顶,药物研发投入长期未见回报,叠加数据泄露事件影响信任,公司申请破产保护。

See the patterns
公开报道整理 待核查 Figures as of 2025 1 sources What do these mean?

How to read this bar

This bar states plainly what we know and what we have checked, so you can judge it yourself.

· Review status: “pending” means no editor has checked it against the sources yet; “checked” means key facts match the sources.

· Figures as of: the year the numbers are current to; later changes are out of scope.

· Sources: listed one by one at the bottom of the page. “Primary” means official filings, annual reports or regulator documents.

· Corrections: every change and its basis is published — nothing is edited silently.

Editorial policy → Editorial policy: the full inclusion rules, verification process, AI disclosure and correction promise.

No English translation for this case yet — showing the stored original.
Peak valuation

消费级基因检测的开创者,累计检测用户超过千万,上市后估值一度达数十亿美元

Final cost

核心检测业务增长见顶,药物研发投入长期未见回报,叠加数据泄露事件影响信任,公司申请破产保护

Attribution votes

5,819 votes cast

Community output

1 plans · 1 insights

Sponsored
把你亲历的失败写进来

投稿会先进入待审,通过后才进入公开目录和站点地图。

Root Causes Consensus Poll

Vote for the primary fatal error that caused this enterprise to collapse.

战略

核心产品是一次性消费缺少复购

用户检测完成后没有持续付费的理由,收入天花板明显

1,914 votes (33%)
资本财务

把数据库价值押注在长周期新药研发上

药物研发周期长、失败率高,与公司的资金能力严重不匹配

1,608 votes (28%)
外部合规

数据安全事件摧毁了用户信任

基因数据的敏感性极高,泄露造成的信任损失难以挽回

1,302 votes (22%)
组织管理

多元化方向与主业能力脱节

从检测转向制药需要完全不同的组织与资金结构

995 votes (17%)

Sources

1 sources

These are the references used to compile this case; the numbers match the [1][2] marks in the timeline. Primary sources come first, and archive links are kept where possible.

  1. [1]
    百度百科:23andMe(DNA鉴定公司) 其他
    百度百科 Accessed 2026-10-05